Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol

BACKGROUND: Approximately 80% to 90% of patients with low-risk rhabdomyosarcoma can be cured. However, cured patients often face long-term complications associated with the treatment. An important factor in the treatment plan is the dose of cyclophosphamide administered because the dose can have bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyachi, Mitsuru, Tsuchiya, Kunihiko, Hosono, Ako, Ogawa, Atsushi, Koh, Katsuyoshi, Kikuta, Atsushi, Hara, Junichi, Teramukai, Satoshi, Hosoi, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946342/
https://www.ncbi.nlm.nih.gov/pubmed/31876708
http://dx.doi.org/10.1097/MD.0000000000018344

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6946342/
https://www.ncbi.nlm.nih.gov/pubmed/31876708
http://dx.doi.org/10.1097/MD.0000000000018344

Ejemplares similares